Analysis BioTech Drug Development 
Healthcare IT Today
APRIL 25, 2024
In our interview, Gil emphasizes the critical role of AI in expediting the discovery of new drugs, citing the lengthy and costly nature of traditional drug development processes. However, with AI-driven approaches, Aion Labs is paving the way for a paradigm shift in drug discovery.
Healthcare IT Today
NOVEMBER 7, 2023
This ML-driven adaptive process can significantly accelerate the clinical drug development process and increase certainty along the way, resulting in more efficient, targeted, and ultimately more successful clinical trials. bringing new needed treatments to patients.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Healthcare IT Today
JANUARY 8, 2024
Given the improvements in costs, trial sponsors can now take advantage of these exchanges at scale and leverage the data for both pre-screening and health economic analysis. As DCTs and virtual site acceptance accelerates, a knock-on effect will be that more of these trials will include HEOR analysis. Dave Latshaw, CEO at BioPhy 1.
Digital Health Global
JUNE 13, 2023
The Beacon Platform unlocks longitudinal, at-home EEG technology, applies machine-learning algorithms to maximize insights into brain activity, and empowers sponsors with comprehensive data analysis and data visualization capabilities.
Lloyd Price
DECEMBER 2, 2024
Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Subscribe Today! Subscribe Today!
Digital Health Global
NOVEMBER 20, 2023
Drawing on AstraZeneca’s deep experience of developing novel therapeutics and with insights from thousands of patients and clinical researchers, Evinova will provide established technology solutions to pharma, biotech and CROs to support clinical research globally. Available at: [link]. Accessed November 2023.
Lloyd Price
DECEMBER 8, 2018
Existing investors include biotech giant Celgene Corp. , Down rounds, where a private company raises money at a price lower than its previous valuation, accounted for 9% of venture financing in the third quarter, according to an analysis by law firm Fenwick & West, while up rounds accounted for 78%.
Expert insights. Personalized for you.
137 
Let's personalize your content